: + 86-21-6100-2280
There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models is an unmet needed in immunotherapy research. As part of PharmaLegacy’s commitment to furthering immuno-oncology research, we have developed a humanized mouse model which harness the human immune system against human tumors.
We reconstitute immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. This humanized mice model provides highly predictive of patient response to novel immunotherapeutic agents.
1. Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of CD34 HSC (hematopoietic stem cells) transplanted-animals.
2. Level of human T cells reconstitution in peripheral blood increased continuously post CD34 HSC transplantation .
Immune checkpoint inhibitors PD-1 and PD-L1 Abs (lead molecules from local R&D collaborators) demonstrated significant inhibitory effects on the growth of HCC-827 human NSCLC cell line.
PD-1 + Her2; PD-1 + Tim3; PD-1 + EGFR; PD-1 + VEGF; PD-1 + CTLA4 and more …
Bi-specific Ab demonstrated significant inhibitory effects on the growth of Raji human Burkitt's lymphoma cell line subcutaneous inoculation.
With fully validated RA models and the state-of-art equipment, PharmaLegacy provides exceptional services for preclinical pharmacology studies of the drug candidates for RA treatment, including:
Oncolytic virus was injected into the right tumor, the left untreated tumor was also associated with a significant reduction in tumor volume.
Demonstration of differential regulation of disease progression and clinical symptoms
